Previous 10 | Next 10 |
--News Direct-- Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr takes Proactive's Stephen Gunnion through progress with the company's lead program, CTIM-76. Lehr explained that CTIM-76 is a T cell engaging bispecific antibody targeting Claudin 6 (CLDN6) on tumor cells and CD3 on...
Company expects its cash and cash equivalents will continue to fund operations into late 2024 Cash and cash equivalents of $25.1 million as of June 30, 2023 CTIM-76 IND filing on track for Q1 2024 PHILADELPHIA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (&...
PHILADELPHIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living with cancer, today announced that Chief Executive Officer Martin Lehr ...
--News Direct-- Context Therapeutics CEO Marty Lehr joins Natalie Stoberman from the Proactive studios to discuss the latest data on clinical cancer target Claudin 6 (CLDN6) presented at ASCO23 and how Context’s CTIM-76 CLDN6 X CD3 bispecific antibody sets itself apart from other C...
2023-06-09 10:07:38 ET Gainers: Sientra ( SIEN ) +65% . ContraFect ( CFRX ) +47% . Societal CDMO ( SCTL ) +20% . Akili ( AKLI ) +14% . Erasca ( ERAS ) +12% . Losers: Elevation Oncology ( ELEV ) -41% . Longboar...
2023-06-08 10:04:22 ET Gainers: Aclarion ( ACON ) +35% . Bone Biologics ( BBLG ) +17% . Atara Biotherapeutics ( ATRA ) +16% . Medigus ( MDGS ) +15% . AVITA Medical ( RCEL ) +13% . Losers: Panbela Therapeutics ( PBLA ) ...
2023-06-05 10:06:47 ET Gainers: Timber Pharmaceuticals ( TMBR ) +36% . Amedisys ( AMED ) +15% . Rockwell Medical ( RMTI ) +15% . Coeptis Therapeutics ( COEP ) +14% . BiondVax Pharmaceuticals ( BVXV ) +12% . Losers: Bellerophon ...
2023-05-10 17:30:51 ET Context Therapeutics press release ( NASDAQ: CNTX ): Q1 GAAP EPS of -$0.40 misses by $0.21 . Cash and cash equivalents were $29.8 million at March 31, 2023, compared to $35.5 million at December 31, 2022. The Company expects its cash and cash...
CTIM-76 IND filing on track for Q1 2024 Preclinical data on CLDN6 bispecific antibody CTIM-76 presented at AACR Annual Meeting 2023 Cash and cash equivalents of $29.8 million as of March 31, 2023 PHILADELPHIA, May 10, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (...
--News Direct-- Context Therapeutics CEO Marty Lehr joins Proactive's Natalie Stoberman to discuss CTIM-76 preclinical data presented at the American Association for Cancer Research (AACR) Annual Meeting 2023. Lehr noted the latest CTIM-76 bispecific antibody data and developments wer...
News, Short Squeeze, Breakout and More Instantly...
Context Therapeutics Inc. Company Name:
CNTX Stock Symbol:
NASDAQ Market:
Context Therapeutics Inc. Website:
CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the ...
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”...